JP2018502899A - Jak阻害剤 - Google Patents
Jak阻害剤 Download PDFInfo
- Publication number
- JP2018502899A JP2018502899A JP2017539364A JP2017539364A JP2018502899A JP 2018502899 A JP2018502899 A JP 2018502899A JP 2017539364 A JP2017539364 A JP 2017539364A JP 2017539364 A JP2017539364 A JP 2017539364A JP 2018502899 A JP2018502899 A JP 2018502899A
- Authority
- JP
- Japan
- Prior art keywords
- group
- pyrrolo
- amino
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 79
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 108
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 68
- 125000001424 substituent group Chemical group 0.000 claims description 38
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000005936 piperidyl group Chemical group 0.000 claims description 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 298
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 232
- 238000006243 chemical reaction Methods 0.000 description 205
- -1 propyl methylene group Chemical group 0.000 description 205
- 239000000203 mixture Substances 0.000 description 201
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 174
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 101
- 235000019439 ethyl acetate Nutrition 0.000 description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 98
- 239000000243 solution Substances 0.000 description 87
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 78
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 78
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 75
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 75
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 74
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 73
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 67
- 239000012043 crude product Substances 0.000 description 66
- 238000004809 thin layer chromatography Methods 0.000 description 65
- 239000012074 organic phase Substances 0.000 description 64
- 239000007787 solid Substances 0.000 description 61
- 238000002953 preparative HPLC Methods 0.000 description 46
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 44
- 239000008346 aqueous phase Substances 0.000 description 44
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 40
- 239000003208 petroleum Substances 0.000 description 38
- 238000000746 purification Methods 0.000 description 38
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 31
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 28
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 28
- 229960000583 acetic acid Drugs 0.000 description 27
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 26
- BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 26
- 229910001873 dinitrogen Inorganic materials 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 24
- 238000003756 stirring Methods 0.000 description 23
- 238000010898 silica gel chromatography Methods 0.000 description 22
- 239000002994 raw material Substances 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 19
- 238000000926 separation method Methods 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000012046 mixed solvent Substances 0.000 description 16
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 125000004429 atom Chemical group 0.000 description 15
- 239000002585 base Substances 0.000 description 15
- 239000012044 organic layer Substances 0.000 description 15
- 239000002253 acid Substances 0.000 description 14
- 125000001072 heteroaryl group Chemical group 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000011259 mixed solution Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical group C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical group OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- BTOJSYRZQZOMOK-UHFFFAOYSA-N 4-chloro-7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=NC(Cl)=C2C=C1 BTOJSYRZQZOMOK-UHFFFAOYSA-N 0.000 description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 10
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 10
- 238000012746 preparative thin layer chromatography Methods 0.000 description 10
- 229910000104 sodium hydride Inorganic materials 0.000 description 10
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 9
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 9
- 235000010288 sodium nitrite Nutrition 0.000 description 9
- 238000004808 supercritical fluid chromatography Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 239000013543 active substance Substances 0.000 description 8
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 8
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 125000006239 protecting group Chemical group 0.000 description 8
- 125000004434 sulfur atom Chemical group 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000004012 Tofacitinib Substances 0.000 description 7
- 230000002378 acidificating effect Effects 0.000 description 7
- 229950006663 filgotinib Drugs 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 description 7
- XJLSEXAGTJCILF-UHFFFAOYSA-N nipecotic acid Chemical compound OC(=O)C1CCCNC1 XJLSEXAGTJCILF-UHFFFAOYSA-N 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229960001350 tofacitinib Drugs 0.000 description 6
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 6
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 5
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 5
- 102000042838 JAK family Human genes 0.000 description 5
- 108091082332 JAK family Proteins 0.000 description 5
- 108010024121 Janus Kinases Proteins 0.000 description 5
- 102000015617 Janus Kinases Human genes 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 125000004430 oxygen atom Chemical group O* 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 4
- KIPSRYDSZQRPEA-UHFFFAOYSA-N 2,2,2-trifluoroethanamine Chemical compound NCC(F)(F)F KIPSRYDSZQRPEA-UHFFFAOYSA-N 0.000 description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- YVZKNKIVBINWAZ-UHFFFAOYSA-N ethyl 1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCN(C1)N(C)C1=NC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 YVZKNKIVBINWAZ-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000011694 lewis rat Methods 0.000 description 4
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 4
- RTITWBGWTASYEG-UHFFFAOYSA-N methyl morpholine-2-carboxylate Chemical compound COC(=O)C1CNCCO1 RTITWBGWTASYEG-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- XJLSEXAGTJCILF-RXMQYKEDSA-N (R)-nipecotic acid zwitterion Chemical compound OC(=O)[C@@H]1CCCNC1 XJLSEXAGTJCILF-RXMQYKEDSA-N 0.000 description 3
- BQDHNUSDBLXYIB-UHFFFAOYSA-N 1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-3-carboxylic acid Chemical compound CN(N1CC(CCC1)C(=O)O)C=1C2=C(N=CN=1)NC=C2 BQDHNUSDBLXYIB-UHFFFAOYSA-N 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- XFKYKTBPRBZDFG-UHFFFAOYSA-N 2-aminoacetonitrile;hydrochloride Chemical compound Cl.NCC#N XFKYKTBPRBZDFG-UHFFFAOYSA-N 0.000 description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- LSOHFHITYPPMAF-UHFFFAOYSA-N ethyl 1-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCN(C1)NC1=NC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 LSOHFHITYPPMAF-UHFFFAOYSA-N 0.000 description 3
- SVPSFBXVRJGKIV-UHFFFAOYSA-N ethyl 1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCN(CC1)N(C)C1=NC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 SVPSFBXVRJGKIV-UHFFFAOYSA-N 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- MPEUOPWWEODARH-UHFFFAOYSA-N ethyl pyrrolidine-3-carboxylate Chemical compound CCOC(=O)C1CCNC1 MPEUOPWWEODARH-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 230000000495 immunoinflammatory effect Effects 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 3
- 125000003373 pyrazinyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 2
- DKMKTPLVHVAYDX-UHFFFAOYSA-N 1-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidine-3-carboxylic acid Chemical compound N1=CN=C(C2=C1NC=C2)NN1CC(CCC1)C(=O)O DKMKTPLVHVAYDX-UHFFFAOYSA-N 0.000 description 2
- ODZGTEOCCGCGKZ-UHFFFAOYSA-N 1-N-methyl-1-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-1,4-diamine Chemical compound CN(N1CCC(N)CC1)C1=NC=NC2=C1C=CN2 ODZGTEOCCGCGKZ-UHFFFAOYSA-N 0.000 description 2
- VKBZBAWGQJMDLU-UHFFFAOYSA-N 1-[1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-3-yl]pyrrolidin-2-one Chemical compound CN(N1CC(CCC1)N1C(CCC1)=O)C=1C2=C(N=CN=1)NC=C2 VKBZBAWGQJMDLU-UHFFFAOYSA-N 0.000 description 2
- QTFJBLQCEDDGKN-UHFFFAOYSA-N 1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-4-carboxylic acid Chemical compound CN(N1CCC(CC1)C(=O)O)C=1C2=C(N=CN=1)NC=C2 QTFJBLQCEDDGKN-UHFFFAOYSA-N 0.000 description 2
- POIBTAFXANMXKU-UHFFFAOYSA-N 1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carbaldehyde Chemical compound CN(N1CCCC(C1)C=O)C1=NC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 POIBTAFXANMXKU-UHFFFAOYSA-N 0.000 description 2
- MMAJXKGUZYDTHV-UHFFFAOYSA-N 1-benzhydrylazetidin-3-ol Chemical compound C1C(O)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 MMAJXKGUZYDTHV-UHFFFAOYSA-N 0.000 description 2
- IDGOMUBINSZWMK-UHFFFAOYSA-N 1-chloro-3-(dibenzylamino)propan-2-ol Chemical compound C=1C=CC=CC=1CN(CC(CCl)O)CC1=CC=CC=C1 IDGOMUBINSZWMK-UHFFFAOYSA-N 0.000 description 2
- YCXCRFGBFZTUSU-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl piperidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 YCXCRFGBFZTUSU-UHFFFAOYSA-N 0.000 description 2
- GSWPLWUWGRVNHN-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl pyrrole-1,3-dicarboxylate Chemical compound CCOC(=O)C=1C=CN(C(=O)OC(C)(C)C)C=1 GSWPLWUWGRVNHN-UHFFFAOYSA-N 0.000 description 2
- AABPATNFGNSNGS-UHFFFAOYSA-N 1-tert-butyl-5-nitroso-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridine-2-carboxylic acid Chemical compound C(C)(C)(C)C1N(CC2CN(CCC21)N=O)C(=O)O AABPATNFGNSNGS-UHFFFAOYSA-N 0.000 description 2
- MVXVYAKCVDQRLW-UHFFFAOYSA-N 1h-pyrrolo[2,3-b]pyridine Chemical compound C1=CN=C2NC=CC2=C1 MVXVYAKCVDQRLW-UHFFFAOYSA-N 0.000 description 2
- DPQNQLKPUVWGHE-UHFFFAOYSA-N 2,2,3,3,3-pentafluoropropan-1-amine Chemical compound NCC(F)(F)C(F)(F)F DPQNQLKPUVWGHE-UHFFFAOYSA-N 0.000 description 2
- OVRWUZYZECPJOB-UHFFFAOYSA-N 2,2-difluoroethanamine Chemical compound NCC(F)F OVRWUZYZECPJOB-UHFFFAOYSA-N 0.000 description 2
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 2
- YDWCTDQRGVZDTD-UHFFFAOYSA-N 3-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-3-azaspiro[5.5]undecane-9-carboxylic acid Chemical compound N1=CN=C(C2=C1NC=C2)NN1CCC2(CC1)CCC(CC2)C(=O)O YDWCTDQRGVZDTD-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- BRIUJWLWVQHTAO-UHFFFAOYSA-N 3-methyl-1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-3-carboxylic acid Chemical compound CC1(CN(CCC1)N(C=1C2=C(N=CN=1)NC=C2)C)C(=O)O BRIUJWLWVQHTAO-UHFFFAOYSA-N 0.000 description 2
- XVPOMRURAXNTJS-UHFFFAOYSA-N 3-oxo-3-[5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridin-2-yl]propanenitrile Chemical compound N1=CN=C(C2=C1NC=C2)NN1CC2C(CC1)CN(C2)C(CC#N)=O XVPOMRURAXNTJS-UHFFFAOYSA-N 0.000 description 2
- JSKCNFVSGLUOMN-UHFFFAOYSA-N 4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]morpholine-2-carboxylic acid Chemical compound CN(N1CC(OCC1)C(=O)O)C=1C2=C(N=CN=1)NC=C2 JSKCNFVSGLUOMN-UHFFFAOYSA-N 0.000 description 2
- RXOUGGMZMDZDCE-UHFFFAOYSA-N 4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(Cl)=C2C=C1 RXOUGGMZMDZDCE-UHFFFAOYSA-N 0.000 description 2
- RZIYWKZWSSFEFI-UHFFFAOYSA-N 4-o-tert-butyl 2-o-methyl morpholine-2,4-dicarboxylate Chemical compound COC(=O)C1CN(C(=O)OC(C)(C)C)CCO1 RZIYWKZWSSFEFI-UHFFFAOYSA-N 0.000 description 2
- KEUTZCYWOMLATR-UHFFFAOYSA-N 5-amino-1-tert-butyl-3,3a,4,6,7,7a-hexahydro-1H-pyrrolo[3,4-c]pyridine-2-carboxylic acid Chemical compound C(C)(C)(C)C1N(CC2CN(CCC21)N)C(=O)O KEUTZCYWOMLATR-UHFFFAOYSA-N 0.000 description 2
- SIRUKCLCFNNLSF-UHFFFAOYSA-N 6-methyl-1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-3-carboxylic acid Chemical compound CC1CCC(CN1N(C=1C2=C(N=CN=1)NC=C2)C)C(=O)O SIRUKCLCFNNLSF-UHFFFAOYSA-N 0.000 description 2
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- MSPBPQFWLVYLHW-UHFFFAOYSA-N N-methyl-N-[3-[5-(trifluoromethyl)-1H-imidazol-2-yl]piperidin-1-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CN(C=1C2=C(N=CN=1)NC=C2)N1CC(CCC1)C=1NC(=CN=1)C(F)(F)F MSPBPQFWLVYLHW-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000006242 amine protecting group Chemical group 0.000 description 2
- 125000005002 aryl methyl group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- JKYMDKBDPAEOLE-UHFFFAOYSA-N bis[2-(3-hydroxyazetidin-1-yl)-1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-3-yl]methanone Chemical compound CN(C1=NC=NC2=C1C=CN2)N3CCCC(C3N4CC(C4)O)C(=O)C5CCCN(C5N6CC(C6)O)N(C)C7=NC=NC8=C7C=CN8 JKYMDKBDPAEOLE-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VLJQZQJRUHVWQF-UHFFFAOYSA-N ethyl 1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-3-carboxylate Chemical compound C(C)OC(=O)C1CN(CCC1)N(C=1C2=C(N=CN=1)NC=C2)C VLJQZQJRUHVWQF-UHFFFAOYSA-N 0.000 description 2
- UABIHSXDHLUMBZ-UHFFFAOYSA-N ethyl 1-aminopiperidine-4-carboxylate Chemical compound CCOC(=O)C1CCN(N)CC1 UABIHSXDHLUMBZ-UHFFFAOYSA-N 0.000 description 2
- WAOWUYVQNBJODC-UHFFFAOYSA-N ethyl 1-aminopyrrolidine-3-carboxylate Chemical compound CCOC(=O)C1CCN(N)C1 WAOWUYVQNBJODC-UHFFFAOYSA-N 0.000 description 2
- OZRQRRQTYYBABB-UHFFFAOYSA-N ethyl 1-nitrosopiperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCN(C1)N=O OZRQRRQTYYBABB-UHFFFAOYSA-N 0.000 description 2
- AOQMXLKHSHYICM-UHFFFAOYSA-N ethyl 1-nitrosopiperidine-4-carboxylate Chemical compound C(C)OC(=O)C1CCN(CC1)N=O AOQMXLKHSHYICM-UHFFFAOYSA-N 0.000 description 2
- ROQCRBFGHUGXCL-UHFFFAOYSA-N ethyl 1-nitrosopyrrolidine-3-carboxylate Chemical compound CCOC(=O)C1CCN(C1)N=O ROQCRBFGHUGXCL-UHFFFAOYSA-N 0.000 description 2
- IIVMIFWDWIPUTH-UHFFFAOYSA-N ethyl 3-azaspiro[5.5]undecane-9-carboxylate Chemical compound C1CC(C(=O)OCC)CCC11CCNCC1 IIVMIFWDWIPUTH-UHFFFAOYSA-N 0.000 description 2
- NUYYXNJBZDSKLB-UHFFFAOYSA-N ethyl 3-methyl-1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound CCOC(=O)C1(C)CCCN(C1)N(C)C1=NC=NC2=C1C=CN2S(=O)(=O)C1=CC=C(C)C=C1 NUYYXNJBZDSKLB-UHFFFAOYSA-N 0.000 description 2
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 2
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 2
- AYYKCALHTPKNOI-UHFFFAOYSA-N ethyl pyrrolidine-3-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1CCNC1 AYYKCALHTPKNOI-UHFFFAOYSA-N 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- KTLGOWLPJPOREV-UHFFFAOYSA-N methyl 1-amino-6-methylpiperidine-3-carboxylate Chemical compound COC(=O)C1CN(C(CC1)C)N KTLGOWLPJPOREV-UHFFFAOYSA-N 0.000 description 2
- HNNYSVNKPACAFF-UHFFFAOYSA-N methyl 4-aminomorpholine-2-carboxylate Chemical compound COC(=O)C1CN(CCO1)N HNNYSVNKPACAFF-UHFFFAOYSA-N 0.000 description 2
- YETHFZYXNPHRPI-UHFFFAOYSA-N methyl 4-nitrosomorpholine-2-carboxylate Chemical compound COC(=O)C1CN(CCO1)N=O YETHFZYXNPHRPI-UHFFFAOYSA-N 0.000 description 2
- WLTKXLLQQWAQND-UHFFFAOYSA-N methyl 6-methyl-1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound COC(=O)C1CCC(C)N(C1)N(C)C1=C2C=CN(C2=NC=N1)S(=O)(=O)C1=CC=C(C)C=C1 WLTKXLLQQWAQND-UHFFFAOYSA-N 0.000 description 2
- AUICTADHNRYUBW-UHFFFAOYSA-N methyl 6-methyl-1-nitrosopiperidine-3-carboxylate Chemical compound COC(=O)C1CN(C(CC1)C)N=O AUICTADHNRYUBW-UHFFFAOYSA-N 0.000 description 2
- AJUGGHOVBBTHCD-UHFFFAOYSA-N methyl 6-methylpiperidine-3-carboxylate Chemical compound COC(=O)C1CCC(C)NC1 AJUGGHOVBBTHCD-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229940080818 propionamide Drugs 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000002755 pyrazolinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VPJZRQUTHWWFHI-UHFFFAOYSA-N tert-butyl 4-amino-1,4-diazepane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CCC1)N VPJZRQUTHWWFHI-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000005309 thioalkoxy group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- 125000000196 1,4-pentadienyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])=C([H])[H] 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- REFCYMTXUSPOOM-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrole-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1C=CC(C(O)=O)=C1 REFCYMTXUSPOOM-UHFFFAOYSA-N 0.000 description 1
- LKFUGSBBEIZGNH-UHFFFAOYSA-N 1-[1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidin-3-yl]pyrrolidin-2-one Chemical compound CN(N1CC(CCC1)N1C(CCC1)=O)C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 LKFUGSBBEIZGNH-UHFFFAOYSA-N 0.000 description 1
- ZOVNXOIYLHXKSH-UHFFFAOYSA-N 1-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylic acid Chemical compound CC1=CC=C(C=C1)S(=O)(=O)N1C=CC2=C(NN3CCCC(C3)C(O)=O)N=CN=C12 ZOVNXOIYLHXKSH-UHFFFAOYSA-N 0.000 description 1
- YEAZGSHBRYBWPD-UHFFFAOYSA-N 1-[cyclopropyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-3-carboxylic acid Chemical compound C1(CC1)N(N1CC(CCC1)C(=O)O)C=1C2=C(N=CN=1)NC=C2 YEAZGSHBRYBWPD-UHFFFAOYSA-N 0.000 description 1
- YPZYZWLQLDCLQV-UHFFFAOYSA-N 1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]pyrrolidine-3-carboxylic acid Chemical compound CN(N1CCC(C1)C(O)=O)C1=C2C=CNC2=NC=N1 YPZYZWLQLDCLQV-UHFFFAOYSA-N 0.000 description 1
- JTOPRNGJYMHHML-UHFFFAOYSA-N 1-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-4-carboxylic acid Chemical compound CN(N1CCC(CC1)C(=O)O)C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 JTOPRNGJYMHHML-UHFFFAOYSA-N 0.000 description 1
- CULGMCOOXGIFEM-UHFFFAOYSA-N 1-aminopiperidine-3-carboxylic acid Chemical compound NN1CCCC(C(O)=O)C1 CULGMCOOXGIFEM-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- MXJSGZQOVOWWST-UHFFFAOYSA-N 1-o-tert-butyl 3-o-ethyl 3-methylpiperidine-1,3-dicarboxylate Chemical compound CCOC(=O)C1(C)CCCN(C(=O)OC(C)(C)C)C1 MXJSGZQOVOWWST-UHFFFAOYSA-N 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CQFIGMZXIFUEPC-UHFFFAOYSA-N 1-tert-butyl-1,3,3a,4,5,6,7,7a-octahydropyrrolo[3,4-c]pyridine-2-carboxylic acid Chemical compound C(C)(C)(C)C1N(CC2CNCCC21)C(=O)O CQFIGMZXIFUEPC-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- UTQNKKSJPHTPBS-UHFFFAOYSA-N 2,2,2-trichloroethanone Chemical group ClC(Cl)(Cl)[C]=O UTQNKKSJPHTPBS-UHFFFAOYSA-N 0.000 description 1
- SFFUEHODRAXXIA-UHFFFAOYSA-N 2,2,2-trifluoroacetonitrile Chemical compound FC(F)(F)C#N SFFUEHODRAXXIA-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- GQAQKKSDJXMOKP-UHFFFAOYSA-N 2-[azido(phenoxy)phosphoryl]oxybenzenesulfonic acid Chemical compound N(=[N+]=[N-])P(=O)(OC1=CC=CC=C1)OC1=C(C=CC=C1)S(=O)(=O)O GQAQKKSDJXMOKP-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- RKVLRYJXUOFTHF-UHFFFAOYSA-N 2-cyano-N-[1-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-4-yl]acetamide Chemical compound C(#N)CC(=O)NC1CCN(CC1)N(C=1C2=C(N=CN=1)NC=C2)C RKVLRYJXUOFTHF-UHFFFAOYSA-N 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RXJJIFUOUWVKTA-UHFFFAOYSA-N 2-methyl-4-oxobutanoic acid Chemical compound OC(=O)C(C)CC=O RXJJIFUOUWVKTA-UHFFFAOYSA-N 0.000 description 1
- CCDHOCSYPLMMBA-UHFFFAOYSA-N 2-methyl-7-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,7-diazabicyclo[3.2.1]octan-6-one Chemical compound CC1N2N(C(C(CC1)C2)=O)C=1C2=C(N=CN=1)NC=C2 CCDHOCSYPLMMBA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HBKYFQUAFRXSSO-UHFFFAOYSA-N 2-piperidin-3-ylacetamide Chemical compound NC(=O)CC1CCCNC1 HBKYFQUAFRXSSO-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- KSNKQSPJFRQSEI-UHFFFAOYSA-N 3,3,3-trifluoropropanoic acid Chemical compound OC(=O)CC(F)(F)F KSNKQSPJFRQSEI-UHFFFAOYSA-N 0.000 description 1
- RKATWUBDSJHPEV-UHFFFAOYSA-N 3,3-difluorocyclobutan-1-amine Chemical compound NC1CC(F)(F)C1 RKATWUBDSJHPEV-UHFFFAOYSA-N 0.000 description 1
- WPYBVVSWXPXZSL-UHFFFAOYSA-N 3-O-tert-butyl 9-O-ethyl 3-azaspiro[5.5]undecane-3,9-dicarboxylate Chemical compound C(C)OC(=O)C1CCC2(CCN(CC2)C(=O)OC(C)(C)C)CC1 WPYBVVSWXPXZSL-UHFFFAOYSA-N 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- LGWMTRPJZFEWCX-UHFFFAOYSA-N 4-[(2-methylpropan-2-yl)oxycarbonyl]morpholine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCOC(C(O)=O)C1 LGWMTRPJZFEWCX-UHFFFAOYSA-N 0.000 description 1
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical group C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- HNTZVGMWXCFCTA-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=NC2=C1C=CN2 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 1
- DUAXUXAXEHSXOH-UHFFFAOYSA-N 6-methyl-1-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidine-3-carboxylic acid Chemical compound CC1CCC(CN1NC=1C2=C(N=CN=1)NC=C2)C(=O)O DUAXUXAXEHSXOH-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- BMZKZBWPMWEQAY-UHFFFAOYSA-N 6h-1,2,5-thiadiazine Chemical compound C1SN=CC=N1 BMZKZBWPMWEQAY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- NOJGUHVPAOKTEK-UHFFFAOYSA-N C1C(C(=O)O)(C)CN(CC1)N Chemical compound C1C(C(=O)O)(C)CN(CC1)N NOJGUHVPAOKTEK-UHFFFAOYSA-N 0.000 description 1
- YMPLSBGGGQKPDD-UHFFFAOYSA-N C1CC(CNN(C1)C(=O)CC(F)(F)F)NC2=NC=NC3=C2C=CN3 Chemical compound C1CC(CNN(C1)C(=O)CC(F)(F)F)NC2=NC=NC3=C2C=CN3 YMPLSBGGGQKPDD-UHFFFAOYSA-N 0.000 description 1
- SUJDGLWJOATMFT-UHFFFAOYSA-N C1CCC2(CC1)CCN(CC2)N=O Chemical compound C1CCC2(CC1)CCN(CC2)N=O SUJDGLWJOATMFT-UHFFFAOYSA-N 0.000 description 1
- RXGRGCZSBDBIIE-UHFFFAOYSA-N CC1(CN(CCC1)N=O)C(=O)O Chemical compound CC1(CN(CCC1)N=O)C(=O)O RXGRGCZSBDBIIE-UHFFFAOYSA-N 0.000 description 1
- RFMIKXIZSXKBBA-UHFFFAOYSA-N CC1=NC2=C(C=CN2)C(=N1)N(C)C(C(F)(F)F)NC(=O)C3CCCNC3 Chemical compound CC1=NC2=C(C=CN2)C(=N1)N(C)C(C(F)(F)F)NC(=O)C3CCCNC3 RFMIKXIZSXKBBA-UHFFFAOYSA-N 0.000 description 1
- DEDFHLCGSQYBEU-UHFFFAOYSA-N CCC(C(CCC1)C(O)=O)N1N(C)C1=NC=NC2=C1C=CN2S(C1=CC=C(C)C=C1)(=O)=O Chemical compound CCC(C(CCC1)C(O)=O)N1N(C)C1=NC=NC2=C1C=CN2S(C1=CC=C(C)C=C1)(=O)=O DEDFHLCGSQYBEU-UHFFFAOYSA-N 0.000 description 1
- SIKWXNSNBZCEOC-UHFFFAOYSA-N CN(C1CCCN(NC1)C(=O)CC(F)(F)F)C2=NC=NC3=C2C=CN3 Chemical compound CN(C1CCCN(NC1)C(=O)CC(F)(F)F)C2=NC=NC3=C2C=CN3 SIKWXNSNBZCEOC-UHFFFAOYSA-N 0.000 description 1
- YUGQNXUUCOBUTO-UHFFFAOYSA-N CN(N1CCN(CCC1)C(CC#N)=C=O)C=1C2=C(N=CN=1)NC=C2 Chemical compound CN(N1CCN(CCC1)C(CC#N)=C=O)C=1C2=C(N=CN=1)NC=C2 YUGQNXUUCOBUTO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- GBRCQYFEUBOLBV-UHFFFAOYSA-N Cl.C(C)OC(=O)C1CN(CCC1)CC Chemical compound Cl.C(C)OC(=O)C1CN(CCC1)CC GBRCQYFEUBOLBV-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical group OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- JGFBQFKZKSSODQ-UHFFFAOYSA-N Isothiocyanatocyclopropane Chemical compound S=C=NC1CC1 JGFBQFKZKSSODQ-UHFFFAOYSA-N 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- CUXBYZRAOFRKCL-UHFFFAOYSA-N N-(1,2,3,3a,4,6,7,7a-octahydropyrrolo[3,4-c]pyridin-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1NCC2CN(CCC21)NC=1C2=C(N=CN=1)NC=C2 CUXBYZRAOFRKCL-UHFFFAOYSA-N 0.000 description 1
- JGGGGNOGMVWUIM-UHFFFAOYSA-N N-(1,4-diazepan-1-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound N1(CCNCCC1)N(C=1C2=C(N=CN=1)NC=C2)C JGGGGNOGMVWUIM-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- NJYLQIDQKFQTGA-UHFFFAOYSA-N N-[3-(aminomethyl)piperidin-1-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CN(N1CCCC(CN)C1)C1=NC=NC2=C1C=CN2 NJYLQIDQKFQTGA-UHFFFAOYSA-N 0.000 description 1
- UUKZKIQNZKRGCG-UHFFFAOYSA-N N1(CCNCCC1)NC=1C2=C(N=CN=1)NC=C2 Chemical compound N1(CCNCCC1)NC=1C2=C(N=CN=1)NC=C2 UUKZKIQNZKRGCG-UHFFFAOYSA-N 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 102100031942 Oncostatin-M Human genes 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000007078 STAT Transcription Factors Human genes 0.000 description 1
- 108010072819 STAT Transcription Factors Proteins 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical group C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical group [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical group 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004935 benzoxazolinyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PWLNAUNEAKQYLH-UHFFFAOYSA-N butyric acid octyl ester Natural products CCCCCCCCOC(=O)CCC PWLNAUNEAKQYLH-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- QGJOPFRUJISHPQ-NJFSPNSNSA-N carbon disulfide-14c Chemical compound S=[14C]=S QGJOPFRUJISHPQ-NJFSPNSNSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical group 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- JWMLCCRPDOIBAV-UHFFFAOYSA-N chloro(methylsulfanyl)methane Chemical compound CSCCl JWMLCCRPDOIBAV-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000005170 cycloalkyloxycarbonyl group Chemical group 0.000 description 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 description 1
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- KBNAWNIUPNOMSU-UHFFFAOYSA-N ethyl 1-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCN(CC1)NC1=C2C=CN(C2=NC=N1)S(=O)(=O)C1=CC=C(C)C=C1 KBNAWNIUPNOMSU-UHFFFAOYSA-N 0.000 description 1
- MCSBNOYPQHDATO-UHFFFAOYSA-N ethyl 1-[cyclopropyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCN(C1)N(C1CC1)C1=C2C=CN(C2=NC=N1)S(=O)(=O)C1=CC=C(C)C=C1 MCSBNOYPQHDATO-UHFFFAOYSA-N 0.000 description 1
- ZSNYQJGHMICFQT-UHFFFAOYSA-N ethyl 1-amino-3-methylpiperidine-3-carboxylate Chemical compound C(C)OC(=O)C1(CN(CCC1)N)C ZSNYQJGHMICFQT-UHFFFAOYSA-N 0.000 description 1
- JMOARFHFBWNPLA-UHFFFAOYSA-N ethyl 1-aminopiperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCN(N)C1 JMOARFHFBWNPLA-UHFFFAOYSA-N 0.000 description 1
- VIKSPABHSACVTJ-UHFFFAOYSA-N ethyl 1-ethyl-3-methylpiperidine-3-carboxylate Chemical compound CCOC(=O)C1(C)CCCN(CC)C1 VIKSPABHSACVTJ-UHFFFAOYSA-N 0.000 description 1
- DUKRWGYNWYSGHR-UHFFFAOYSA-N ethyl 3-amino-3-azaspiro[5.5]undecane-9-carboxylate Chemical compound C(C)OC(=O)C1CCC2(CCN(CC2)N)CC1 DUKRWGYNWYSGHR-UHFFFAOYSA-N 0.000 description 1
- MNBPMKXGNJWECS-UHFFFAOYSA-N ethyl 3-methyl-1-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound CCOC(=O)C1(C)CCCN(C1)NC1=C2C=CN(C2=NC=N1)S(=O)(=O)C1=CC=C(C)C=C1 MNBPMKXGNJWECS-UHFFFAOYSA-N 0.000 description 1
- WYPLHKNXBJALRX-UHFFFAOYSA-N ethyl 3-methyl-1-nitrosopiperidine-3-carboxylate Chemical compound C(C)OC(=O)C1(CN(CCC1)N=O)C WYPLHKNXBJALRX-UHFFFAOYSA-N 0.000 description 1
- LNANFKKPVLUIBX-UHFFFAOYSA-N ethyl 3-methylpiperidine-3-carboxylate Chemical compound CCOC(=O)C1(C)CCCNC1 LNANFKKPVLUIBX-UHFFFAOYSA-N 0.000 description 1
- IEXXIYWFTDOTMZ-UHFFFAOYSA-N ethyl 3-nitroso-3-azaspiro[5.5]undecane-9-carboxylate Chemical compound N(=O)N1CCC2(CC1)CCC(CC2)C(=O)OCC IEXXIYWFTDOTMZ-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- XIWBSOUNZWSFKU-UHFFFAOYSA-N ethyl piperidine-3-carboxylate Chemical compound CCOC(=O)C1CCCNC1 XIWBSOUNZWSFKU-UHFFFAOYSA-N 0.000 description 1
- ZCEGLOKZSLNARG-UHFFFAOYSA-N ethyl piperidine-3-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1CCCNC1 ZCEGLOKZSLNARG-UHFFFAOYSA-N 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- JVZRCNQLWOELDU-UHFFFAOYSA-N gamma-Phenylpyridine Natural products C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- UXTNOZHAXMNTPN-UHFFFAOYSA-N methyl 4-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]morpholine-2-carboxylate Chemical compound COC(=O)C1CN(CCO1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 UXTNOZHAXMNTPN-UHFFFAOYSA-N 0.000 description 1
- AKZVLOYTRXRPHM-UHFFFAOYSA-N methyl 4-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]morpholine-2-carboxylate Chemical compound COC(=O)C1CN(CCO1)N(C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C AKZVLOYTRXRPHM-UHFFFAOYSA-N 0.000 description 1
- NJGYOXCBBXKWDB-UHFFFAOYSA-N methyl 6-methyl-1-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]piperidine-3-carboxylate Chemical compound COC(=O)C1CN(C(CC1)C)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 NJGYOXCBBXKWDB-UHFFFAOYSA-N 0.000 description 1
- VYPPZXZHYDSBSJ-UHFFFAOYSA-N methyl 6-methylpyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(C)N=C1 VYPPZXZHYDSBSJ-UHFFFAOYSA-N 0.000 description 1
- BCDBHIAXYFPJCT-UHFFFAOYSA-N methyl piperidine-3-carboxylate Chemical compound COC(=O)C1CCCNC1 BCDBHIAXYFPJCT-UHFFFAOYSA-N 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 1
- UUIQMZJEGPQKFD-UHFFFAOYSA-N n-butyric acid methyl ester Natural products CCCC(=O)OC UUIQMZJEGPQKFD-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical group C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- PEUGKEHLRUVPAN-UHFFFAOYSA-N piperidin-3-amine Chemical compound NC1CCCNC1 PEUGKEHLRUVPAN-UHFFFAOYSA-N 0.000 description 1
- ITYKBOIQLYMDTI-UHFFFAOYSA-N piperidin-3-amine;hydrochloride Chemical compound Cl.NC1CCCNC1 ITYKBOIQLYMDTI-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000004928 piperidonyl group Chemical group 0.000 description 1
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 1
- IQHXABCGSFAKPN-UHFFFAOYSA-N pyrrolidine-3-carboxamide Chemical compound NC(=O)C1CCNC1 IQHXABCGSFAKPN-UHFFFAOYSA-N 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000006253 t-butylcarbonyl group Chemical group [H]C([H])([H])C(C(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- ZSNGKAZBLKKZOC-UHFFFAOYSA-N tert-butyl 4-[[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]-1,4-diazepane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CCC1)NC=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1 ZSNGKAZBLKKZOC-UHFFFAOYSA-N 0.000 description 1
- GHPOKFNCUCNOBS-UHFFFAOYSA-N tert-butyl 4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-1,4-diazepane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CCC1)N(C=1C2=C(N=CN=1)NC=C2)C GHPOKFNCUCNOBS-UHFFFAOYSA-N 0.000 description 1
- VILNYYHSVGQNHP-UHFFFAOYSA-N tert-butyl 4-[methyl-[7-(4-methylphenyl)sulfonylpyrrolo[2,3-d]pyrimidin-4-yl]amino]-1,4-diazepane-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1CCN(CCC1)N(C=1C2=C(N=CN=1)N(C=C2)S(=O)(=O)C1=CC=C(C)C=C1)C VILNYYHSVGQNHP-UHFFFAOYSA-N 0.000 description 1
- OMVVDPDHWDSHSO-UHFFFAOYSA-N tert-butyl formate 1-nitroso-1,4-diazepane Chemical compound CC(C)(C)OC=O.O=NN1CCCNCC1 OMVVDPDHWDSHSO-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- SYIKUFDOYJFGBQ-YLAFAASESA-N tofacitinib citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 SYIKUFDOYJFGBQ-YLAFAASESA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229940039916 xeljanz Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
環Aは、任意に置換された5〜12員のヘテロシクロアルキル基又は5〜6員のヘテロアリール基から選択され;
R1は、H又は任意に置換されたC1−6アルキル基、C1−6ヘテロアルキル基、C3−6シクロアルキル基、3〜6員のヘテロシクロアルキル基、5〜6員のアリール基、若しくは5〜6員のヘテロアリール基から選択され;
Lは、単結合、−C(=O)O−、アシル基、又は、任意に置換されたアミノ基、アミノアシル基、アシルアミノメチレン基、アミノアシルメチレン基から選択され;任意に、R1は、LにおけるNと任意に置換された3〜6員の環を形成し;
R2は、H又は任意に置換されたC1−3アルキル基、3〜6員のシクロアルキル基から選択され;
任意に、構造単位
は、
に置換され;
「ヘテロ」は、O、S又はNを表し、その数は1、2、又は3である。
から選択される。
から選択される。
C1−2アルキル基−O−C1−2アルキル基−、C1−2アルキル基−S−C1−2アルキル基−、イミダゾール基、フェニル基から選択される。
から選択される。
から選択される。
から選択される。
から選択される。
別途に説明しない限り、本明細書に使用される用語及び連語は、以下の意味を有する。一つの特定の用語又は連語は、特別に定義されていない場合、不確定又は不明瞭ではなく、普通の定義として理解されるべきである。本明細書に商品名が現れた場合、対応の商品又はその活性成分を指す。
−CH2CH(OH)(CH3)2,−CH2CH(F)(CH3)2,−CH2CH2F,−CH2CF3,−CH2CH2CF3,−CH2CH2NH2,−CH2CH2OH,−CH2CH2OCH3,−CH2CH2CH2OCH3,−CH2CH2N(CH3)2,−S(=O)2CH3,−CH2CH2S(=O)2CH3;及び
1−((7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,2−トリフルオロエチル)ピペリジン−3−ホルムアミド
N−メチル−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−(2,2,2−トリフルオロエチル)ピペリジン−3−ホルムアミド
1−((7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(シアノメチル)ピペリジン−3−ホルムアミド
1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,−トリフルオロエチル)ピペリジン−3−ホルムアミド
(R&S)1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,−トリフルオロエチル)ピペリジン−3−ホルムアミド
カラム:AS−Hキラルカラム
移動相:A:超臨界CO2、B:20%EtOH(0.1%NH3・H2O)、A:B=50:50
流速:60mL/min
カラム温度:38℃
波長:220nm
射出圧力:100Bar
ノズル温度:60℃
蒸発温度:20℃
補正温度:25℃
(N−(シアノメチル)−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
(R&S)(N−(シアノメチル)−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
分離カラム:AS−H
移動相:A:超臨界CO2、B:30%MeOH(0.1%NH3・H2O)、A:B=50:50
流速:50mL/min
カラム温度:38℃
波長:220nm
射出圧力:100Bar
ノズル温度:60℃
蒸発温度:20℃
補正温度:25℃
1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−カルボン酸エチルエステル
1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]ピペリジン−3−ホルムアミド
2−シアノ−N−(1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−アセトアミド
3,3,3−トリフルオロ−N−(1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−)プロピオンアミド
N−(シアノメチル)−1−(メチル(1H−ピロロ[2,3−b]ピリジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
N−(2,2,2−トリフルオロエチル)−1−(メチル(1H−ピロロ[2,3−b]ピリジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
N−(シアノエチル)−1−(メチル(1H−ピロロ[2,3−b]ピリジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
N−(2,2,2−トリフルオロエチル)−2−(1−(メチル(7−p−トルエンスルホニル−7H−ピロロ[2,3−b]ピリミジン−4−イル)アミノ)ピペリジン−3−イル)アセトアミド
N−(シアノメチル)−2−(1−(メチル(7−p−トルエンスルホニル−7H−ピロロ[2,3−b]ピリミジン−4−イル)アミノ)ピペリジン−3−イル)アセトアミド
3,3,3−トリフルオロ−N−((1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−)アミノ)ピペリジン−3−)メチル)プロパンアミド
N−(シアノメチル)−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−4−ホルムアミド
2−シアノ−N−(1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−4−イル)アセトアミド
N−(シアノメチル)−6−メチル−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
を得た。1HNMR(400MHz,メタノール−d4)δ=8.48(s,1H),7.47(d,J=3.6Hz,1H),7.01(d,J=3.6Hz,1H),4.25−4.35(m,2H),3.59(s,3H),3.17−3.24(m,1H),3.09−3.16(m,1H),2.99−3.08(m,1H),2.95(br.s.,1H),2.04−2.14(m,1H),1.78−1.96(m,2H),1.45−1.59(m,1H),0.99(d,J=6.4Hz,3H)。MS ESI計算値はC16H21N7O2[M+H]+328で、測定値は328である。
6−メチル−1−(メチル(7H−ピロロ[2.3−d]ピリミジン−4−イル)アミン)−N−(2,2,2−トリフルオロエチル)ピペリジン−3−ホルムアミド
2−メチル−7−(7H−ピロロ[2,3−d]ピリミジン−4−イル)−1,7−ジアザビシクロ[3.2.1]オクタン−6ケトン
1−(1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−イル)−ピロリジン−2−オン
N−(シアノメチル)−1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]ピロリジン−3−ホルムアミド
1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2,2トリフルオロエチル)ピロリジン−3−ホルムアミド
(R&S)1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2,2トリフルオロエチル)ピロリジン−3−ホルムアミド
カラム:AD(250mm*30mm、5um)キラルカラム
移動相:A:超臨界CO2、B:20%MeOH(0.1%NH3・H2O)、A:B=80:20
流速:60mL/min
カラム温度:38℃
波長:220nm
射出圧力:100Bar
ノズル温度:60℃
蒸発温度:20℃
補正温度:25℃
3−(4−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−1,4−ジアゼパン−1−イル)−3−カルボニルプロパンニトリル
1−(4−((7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−ジアゼパン−1−イル)−3,3,3−トリフルオロプロパン−1−オン
3,3,3−トリフルオロ−1−(4−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−ジアゼパン−1−イル)プロパン−1−オン
N−(シアノメチル)−3−メチル−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−ホルムアミド
3−メチル−1−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,2−トリフルオロエチル)ピペリジン−3−ホルムアミド
N−(シアノエチル)−4−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)モルホリン−2−ホルムアミド
4−((7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,2−トリフルオロエチル)モルホリン−2−ホルムアミド
4−(メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,2−トリフルオロエチル)モルホリン−2−ホルムアミド
N−(メトキシメチル)−1−[メチル−(7H−ピロロ[2,3−d]ピリミジン−4−]アミノ]ピペリジン−3−ホルムアミド
1−[メチル−[7H−ピロロ[2,3−d]ピリミジン−4−]アミノ]−N−(メチルチオメチル)ピペリジン−3−ホルムアミド
2−[1−[メチル[7H−ピロロ[2,3−d]ピリミジン−4−]アミノ]−3−ピペリジン]アセトニトリル
2−シアノ−N−((メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ)ピペリジン−3−イル)メチル)アセトアミド
1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2,3,3,3−ペンタフルオロプロパン)ピペリジン−3−ホルムアミド
1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2−ジフルオロメチル)ピペリジン−3−ホルムアミド
5−[[7H−ピロロ[2,3−d]ピリミジン−4−]アミノ]−ヘキサヒドロピロロ[3,4−c]ピロール−2(1H)−ぎ酸tert−ブチル
(3S又は3R)−1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2−ジフルオロメチル)ピペリジン−3−ホルムアミド
カラム:AD(250mm*30mm、5um)キラルカラム
移動相:A:超臨界CO2、B:30%MeOH(0.1%NH3・H2O)、A:B=70:30
流速:80mL/min
カラム温度:38℃
波長:220nm
射出圧力:100Bar
ノズル温度:60℃
蒸発温度:20℃
補正温度:25℃
(3S又は3R)−1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2,3,3,3−ペンタフルオロプロパン)ピペリジン−3−ホルムアミド
カラム:AD(250mm*30mm、10um)キラルカラム
移動相:A:超臨界CO2、B:40%MeOH(0.1%NH3・H2O)、A:B=60:40
流速:70mL/min
カラム温度:38℃
波長:220nm
射出圧力:100Bar
ノズル温度:60℃
蒸発温度:20℃
補正温度:25℃
1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−[3−(トリフロロメチル)フェニル]ピペリジン−3−ホルムアミド
(3−ヒドロキシルアゼチジン−1−イル)−[1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ〕−3−ピペリジル〕ケトン
3−[5−(7H−ピロロ[2,3−d]ピリミジン−4−イルアミノ)−ヘキサヒドロ−1H−ピロロ[3,4−c]ピリジン−2−イル]3−オキソプロパンニトリル
N−(3,3−ジフルオロシクロブチル)−1−[メチル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]ピペリジン−3−ホルムアミド
N−メチル−N−[3−[5−トリフロロメチル−1H−イミダゾール−2−イル]−1−ピペリジル]−7H−ピロロ[2,3−d]ピリミジン−4−アミン
1−[シクロプロピル(7H−ピロロ[2,3−d]ピリミジン−4−イル)アミノ]−N−(2,2,2−トリフルオロエチル)ピペリジン−3−ホルムアミド
3−(7Hピロロ[2,3−d]ピリミジン−4−イル)アミノ)−N−(2,2,2−トリフルオロエチル)−3−アザスピロ[5.5]ウンデカン−9−ホルムアミド
試験材料
組換え体タンパク質JAK1、JAK2、JAK3プロテアーゼは、Lifetechnology社から購入し、「LANCE Ultra ULight」(商標)−JAK−1(Tyr1023)ペプチド及びLANCE Eu−W1024 Anti−phosphotyrosine(PT66)は、Perkin Elmer社から購入した。読み取りは、マイクロプレートリーダーEnvision(Perkin Elmer)で実施した。
被験化合物を濃度勾配で3倍希釈して、最終濃度は10uM〜0.17nM11で、各濃度で二個のウェルを設けた。測定反応におけるDMSOの含有量は1%である。
2nM;JAK1プロテインキナーゼ、50nM;「LANCE Ultra ULight」(商標)−JAK−1(Tyr1023)ペプチド、38μM;ATP、50mM;HEPES(pH7.5)、10mM;MgCl2、1mM;EGTA、2mM;DTT、0.01%;BRIJ−35。ウェルプレートはWhite Proxiplate 384−Plus plate(Perkin Elmer)で、室温で90分間反応させ、反応体系は10μlである。
0.02nM;JAK2プロテインキナーゼ、50nM;「LANCE Ultra ULight」(商標)−JAK−1(Tyr1023)ペプチド、12μM;ATP、50mM;HEPES(pH7.5)、10mM;MgCl2、1mM;EGTA、2mM;DTT、0.01%;BRIJ−35。ウェルプレートはWhite Proxiplate 384−Plus plate(Perkin Elmer)で、室温で90分間反応させ、反応体系は10μlである
0.05nM;JAK2プロテインキナーゼ、50nM;「LANCE Ultra ULight」(商標)−JAK−1(Tyr1023)ペプチド、4μM;ATP、50mM;HEPES(pH7.5)、10mM;MgCl2、1mM;EGTA、2mM;DTT、0.01%;BRIJ−35。ウェルプレートはWhite Proxiplate 384−Plus plate(Perkin Elmer)で、室温で90分間反応させ、反応体系は10μlである。
測定試薬10μlをウェルプレートに添加して、ここで、LANCE Eu−W1024 Anti−phosphotyrosine(PT66)の最終濃度は2nMで、EDTAの最終濃度は10mMで、室温で60分間インキュベートさせた。読み取りは、Envisionで実施した。
阻害率(%)=(Min−Ratio)/(Max−Min)*100%という公式でリード数を阻害率(%)に変換した。4つのパラメートの曲線あてはめ(Model 205 in XLFIT5、iDBS)でIC50を測定した。詳細を表1に示す。
被験化合物を溶解させて得られた澄んだ液体を、それぞれ尾静脈注射及び胃内投与によって雄DBA/1マウス体内に投与した(夜断食、7〜8週齢)。被験化合物を投与した後、静脈注射群は0.083、0.25、0.5、1、2、4、8及び24時間で、胃内投与群は0.25、0.5、1、2、4、8及び24時間で、それぞれ下顎静脈から採血し遠心分離によって血漿を得た。LC−MS/MSを用いて血漿濃度を測定し、薬物動態学的解析ソフト「WinNonlin(商標) Version 6.3」を用いて、ノンコンパートメントモデルの対数線形台形法で薬物動態学的パラメータを算出した。被験化合物をPEG400/水(20%/80%)に溶解させて得られた上澄液を、それぞれ尾静脈注射及び胃内投与によって雌Lewisラット体内に投与した(夜断食、7〜8週齢)。被験化合物を投与した後、静脈注射群は0.083、0.25、0.5、1、2、4、8及び24時間で、胃内投与群は0.25、0.5、1、2、4、8及び24時間で、それぞれ下顎静脈から採血し遠心分離によって血漿を得た。LC−MS/MSを用いて血漿濃度を測定し、薬物動態学的解析ソフト「WinNonlin(商標) Version 6.3」を用いて、ノンコンパートメントモデルの対数線形台形法で薬物動態学的パラメータを算出した。
アジュバント誘発のラット関節炎モデルを用いて、本発明に係る化合物の関節炎に対する治療効果を検証した。
コラーゲン誘発のマウス関節炎モデルを用いて、本発明に係る化合物の関節炎に対する治療効果を検証した。
Claims (10)
- 式(I)で示される化合物又はその薬学的に許容される塩:
式中、
環Aは、任意に置換された5〜12員のヘテロシクロアルキル基又は5〜6員のヘテロアリール基から選択され;
R1は、H又は任意に置換されたC1−6アルキル基、C1−6ヘテロアルキル基、C3−6シクロアルキル基、3〜6員のヘテロシクロアルキル基、5〜6員のアリール基、若しくは5〜6員のヘテロアリール基から選択され;
Lは、単結合、−C(=O)O−、アシル基、又は、任意に置換されたアミノ基、アミノアシル基、アシルアミノメチレン基、アミノアシルメチレン基から選択され;任意に、R1は、LにおけるNと任意に置換された3〜6員の環を形成し;
R2は、H又は任意に置換されたC1−3アルキル基、3〜6員のシクロアルキル基から選択され;
任意に、構造単位
は、
に置換され;
「ヘテロ」は、O、S又はNを表し、その数は1、2、又は3である。 - 前記5〜10員のヘテロシクロアルキル、5〜6員のヘテロアリール基、C1−6アルキル基、C1−6ヘテロアルキル基、C3−6シクロアルキル基、3〜6員のヘテロシクロアルキル基、5〜6員のアリール基、5〜6員のヘテロアリール基、アミノ基、アミノアシル基、アシルアミノメチレン基、アミノアシルメチレン基、C1−3アルキル基、3〜6員の環の置換基は、ハロゲン、シアノ基、ヒドロキシル基、アミノ基から選択され、又は任意にハロゲン、ヒドロキシル、及び/若しくはアミノで置換されたC1−3アルキル基、C1−3ヘテロアルキル基から選択され、
置換基の数は0、1、2、3、4、又は5であり、
具体的に、置換基は、F、Cl、Br、I、OH、NH2、CN、Me、エチル基、プロピル基、イソプロピル基、シクロプロピル基、トリフルオロメチル基から選択される、請求項1に記載の化合物又はその薬学的に許容される塩。 - 環Aは、任意に置換された、ピペリジル基、ピペラジニル基、モルホリニル基、ピロリジニル基、オキサゾリル基、ヘテロ原子を1〜2個含有する7〜12員のヘテロシクロ基から選択される、請求項1又は2に記載の化合物又はその薬学的に許容される塩。
- 環Aは、任意に置換された
から選択され、
具体的に、環Aは、
から選択される、請求項3に記載の化合物又はその薬学的に許容される塩。 - R1は、H又は任意に置換された、C1−4アルキル基、C1−2アルキル基−O−C1−2アルキル基−、C1−2アルキル基−S−C1−2アルキル基−、C4−5シクロアルキル基、6員のアリール基、又は5員のヘテロアリール基から選択され、
具体的に、R1は、H又は任意に置換された、Me、
C1−2アルキル基−O−C1−2アルキル基−、C1−2アルキル基−S−C1−2アルキル基−、イミダゾール基、フェニル基から選択され、
より具体的に、R1は、H、
から選択される,請求項1又は2に記載の化合物又はその薬学的に許容される塩。 - R1は、L中のNと任意に置換された4〜5員の環を形成し、
具体的に、R1がL中のNと形成される環は、任意に置換された
から選択される、請求項1に記載の化合物又はその薬学的に許容される塩。 - R1−L−は、任意に置換された、Me、
から選択され、
具体的に、R1−L−は、
から選択される、請求項1に記載の化合物又はその薬学的に許容される塩。 - R2は、H、メチル基、エチル基、又はシクロプロピル基から選択される、請求項1又は2に記載の化合物又はその薬学的に許容される塩。
- 具体的に、
- JAK関連疾患を治療するための薬剤の製造における、請求項1〜9のいずれか1項に記載の化合物又はその薬学的に許容される塩の使用。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510029259 | 2015-01-20 | ||
CN201510029259.3 | 2015-01-20 | ||
CN201610016564 | 2016-01-11 | ||
CN201610016564.3 | 2016-01-11 | ||
PCT/CN2016/071313 WO2016116025A1 (zh) | 2015-01-20 | 2016-01-19 | Jak抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018502899A true JP2018502899A (ja) | 2018-02-01 |
JP6742323B2 JP6742323B2 (ja) | 2020-08-19 |
Family
ID=56416433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017539364A Active JP6742323B2 (ja) | 2015-01-20 | 2016-01-19 | Jak阻害剤 |
Country Status (15)
Country | Link |
---|---|
US (1) | US10617690B2 (ja) |
EP (1) | EP3248980B1 (ja) |
JP (1) | JP6742323B2 (ja) |
KR (1) | KR101864561B1 (ja) |
CN (1) | CN108349977B (ja) |
AU (1) | AU2016208906B2 (ja) |
CA (1) | CA2979425C (ja) |
EA (1) | EA036122B1 (ja) |
ES (1) | ES2962330T3 (ja) |
HU (1) | HUE064003T2 (ja) |
MX (1) | MX2017009449A (ja) |
PL (1) | PL3248980T3 (ja) |
TW (1) | TWI690531B (ja) |
UA (1) | UA118149C2 (ja) |
WO (1) | WO2016116025A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021518379A (ja) * | 2018-03-21 | 2021-08-02 | リャオ, シビンLiao, Xibin | Jak阻害剤 |
JP2022506682A (ja) * | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ,インコーポレーテッド | 化合物 |
JP2022518556A (ja) * | 2019-02-02 | 2022-03-15 | 江蘇威凱爾医薬科技有限公司 | ヤーヌスキナーゼ(jak)ファミリー阻害剤及びその調製と使用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017366400B2 (en) * | 2016-11-23 | 2021-08-26 | Jiangsu Hengrui Medicine Co., Ltd. | Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative |
CN107602591A (zh) * | 2017-10-31 | 2018-01-19 | 无锡福祈制药有限公司 | 一种Janus激酶3抑制剂 |
CN107778321A (zh) * | 2017-10-31 | 2018-03-09 | 无锡福祈制药有限公司 | 一种托法替尼类似物 |
CN107573364A (zh) * | 2017-10-31 | 2018-01-12 | 无锡福祈制药有限公司 | 一种jak激酶抑制剂 |
CN107805259A (zh) * | 2017-10-31 | 2018-03-16 | 无锡福祈制药有限公司 | 一种吡咯并嘧啶类化合物 |
CN107652308A (zh) * | 2017-10-31 | 2018-02-02 | 无锡福祈制药有限公司 | 一种Janus激酶3抑制剂 |
CN107602590A (zh) * | 2017-10-31 | 2018-01-19 | 无锡福祈制药有限公司 | 具有Janus激酶抑制活性的桥环化合物 |
WO2020156271A1 (zh) | 2019-02-02 | 2020-08-06 | 江苏威凯尔医药科技有限公司 | 两面神激酶jak家族抑制剂及其制备和应用 |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
CN113993585B (zh) * | 2019-03-27 | 2024-10-01 | 英矽智能科技知识产权有限公司 | 双环jak抑制剂及其用途 |
AU2020288567B2 (en) * | 2019-06-05 | 2023-06-15 | Guangzhou Joyo Pharmatech Co., Ltd | Pyrrolopyrimidine compound and use thereof |
CN112480116B (zh) * | 2019-09-11 | 2024-03-29 | 南京正大天晴制药有限公司 | Pkb抑制剂 |
CN110483514B (zh) * | 2019-09-16 | 2022-06-14 | 启元生物(杭州)有限公司 | 一种氰基取代的环肼衍生物及其应用 |
CN110724142B (zh) * | 2019-10-29 | 2022-09-02 | 启元生物(杭州)有限公司 | 一种作为jak激酶抑制剂的酰胺或磺酰胺取代的肼衍生物 |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
CN112168827A (zh) * | 2020-11-03 | 2021-01-05 | 卓和药业集团有限公司 | 一种用于治疗银屑病的药物组合物及其制备方法 |
CN113372343B (zh) * | 2020-12-04 | 2022-07-29 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物中间体及其制备方法 |
CN113372366B (zh) * | 2020-12-04 | 2022-08-30 | 广州嘉越医药科技有限公司 | 一种吡咯并嘧啶类化合物的盐、其晶型及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003077921A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
JP2004501922A (ja) * | 2000-06-26 | 2004-01-22 | ファイザー・プロダクツ・インク | 免疫抑制剤としてのピロロ(2,3−d)ピリミジン化合物 |
JP2006501200A (ja) * | 2002-07-23 | 2006-01-12 | スミスクライン ビーチャム コーポレーション | キナーゼインヒビターとしてのピラゾロピリミジン |
WO2007102679A1 (en) * | 2006-03-06 | 2007-09-13 | Je Il Pharmaceutical Co., Ltd. | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
JP2008069149A (ja) * | 2006-09-05 | 2008-03-27 | Pfizer Prod Inc | リウマチ様関節炎のための併用療法 |
WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
WO2014003483A1 (en) * | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
MEP35308A (en) | 2000-12-01 | 2011-02-10 | Osi Pharm Inc | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2a, AND A3 RECEPTOR AND USES THEREOF |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
MX2011001904A (es) | 2008-08-20 | 2011-03-29 | Pfizer | Compuestos de pirrolo[2,3-d]pirimidina. |
KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘 |
JP2014528475A (ja) | 2011-10-12 | 2014-10-27 | アレイ バイオファーマ、インコーポレイテッド | 5,7置換イミダゾ[1,2−c]ピリミジン |
US8551542B1 (en) | 2012-09-20 | 2013-10-08 | Basic Research L.L.C. | Methods and compositions for increasing growth hormones |
IN2013MU03843A (ja) | 2013-12-09 | 2015-08-14 | Unichem Lab Ltd |
-
2016
- 2016-01-19 PL PL16739772.8T patent/PL3248980T3/pl unknown
- 2016-01-19 JP JP2017539364A patent/JP6742323B2/ja active Active
- 2016-01-19 CN CN201680014178.9A patent/CN108349977B/zh active Active
- 2016-01-19 EP EP16739772.8A patent/EP3248980B1/en active Active
- 2016-01-19 HU HUE16739772A patent/HUE064003T2/hu unknown
- 2016-01-19 MX MX2017009449A patent/MX2017009449A/es unknown
- 2016-01-19 US US15/545,245 patent/US10617690B2/en active Active
- 2016-01-19 ES ES16739772T patent/ES2962330T3/es active Active
- 2016-01-19 UA UAA201708428A patent/UA118149C2/uk unknown
- 2016-01-19 KR KR1020177023156A patent/KR101864561B1/ko active IP Right Grant
- 2016-01-19 WO PCT/CN2016/071313 patent/WO2016116025A1/zh active Application Filing
- 2016-01-19 AU AU2016208906A patent/AU2016208906B2/en active Active
- 2016-01-19 EA EA201791576A patent/EA036122B1/ru unknown
- 2016-01-19 CA CA2979425A patent/CA2979425C/en active Active
- 2016-01-20 TW TW105101739A patent/TWI690531B/zh active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004501922A (ja) * | 2000-06-26 | 2004-01-22 | ファイザー・プロダクツ・インク | 免疫抑制剤としてのピロロ(2,3−d)ピリミジン化合物 |
WO2003077921A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Azinylaminoazoles as inhibitors of protein kinases |
JP2006501200A (ja) * | 2002-07-23 | 2006-01-12 | スミスクライン ビーチャム コーポレーション | キナーゼインヒビターとしてのピラゾロピリミジン |
WO2007102679A1 (en) * | 2006-03-06 | 2007-09-13 | Je Il Pharmaceutical Co., Ltd. | Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same |
JP2008069149A (ja) * | 2006-09-05 | 2008-03-27 | Pfizer Prod Inc | リウマチ様関節炎のための併用療法 |
WO2008144253A1 (en) * | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
WO2014003483A1 (en) * | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
Non-Patent Citations (1)
Title |
---|
"RN 1347555-42-3", DATABASE REGISTRY[ONLINE], JPN7018001955, 2 December 2011 (2011-12-02), ISSN: 0003816407 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021518379A (ja) * | 2018-03-21 | 2021-08-02 | リャオ, シビンLiao, Xibin | Jak阻害剤 |
JP7462951B2 (ja) | 2018-03-21 | 2024-04-08 | リャオ,シビン | Jak阻害剤 |
JP2022506682A (ja) * | 2018-11-05 | 2022-01-17 | アビスタ ファーマ ソリューションズ,インコーポレーテッド | 化合物 |
JP2022518556A (ja) * | 2019-02-02 | 2022-03-15 | 江蘇威凱爾医薬科技有限公司 | ヤーヌスキナーゼ(jak)ファミリー阻害剤及びその調製と使用 |
JP7344304B2 (ja) | 2019-02-02 | 2023-09-13 | 江蘇威凱爾医薬科技有限公司 | ヤーヌスキナーゼ(jak)ファミリー阻害剤及びその調製と使用 |
Also Published As
Publication number | Publication date |
---|---|
CA2979425A1 (en) | 2016-07-28 |
MX2017009449A (es) | 2018-05-28 |
CN108349977B (zh) | 2021-05-25 |
CA2979425C (en) | 2020-04-14 |
UA118149C2 (uk) | 2018-11-26 |
TW201627309A (zh) | 2016-08-01 |
EP3248980A1 (en) | 2017-11-29 |
US20170360794A1 (en) | 2017-12-21 |
HUE064003T2 (hu) | 2024-02-28 |
CN108349977A (zh) | 2018-07-31 |
EP3248980C0 (en) | 2023-09-06 |
JP6742323B2 (ja) | 2020-08-19 |
EA036122B1 (ru) | 2020-09-30 |
KR101864561B1 (ko) | 2018-06-04 |
TWI690531B (zh) | 2020-04-11 |
AU2016208906A1 (en) | 2017-08-31 |
AU2016208906B2 (en) | 2018-07-12 |
ES2962330T3 (es) | 2024-03-18 |
EA201791576A1 (ru) | 2018-03-30 |
EP3248980A4 (en) | 2018-08-01 |
EP3248980B1 (en) | 2023-09-06 |
KR20170101309A (ko) | 2017-09-05 |
WO2016116025A1 (zh) | 2016-07-28 |
US10617690B2 (en) | 2020-04-14 |
PL3248980T3 (pl) | 2024-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6742323B2 (ja) | Jak阻害剤 | |
JP6600365B2 (ja) | Jak阻害剤 | |
CN107531711B (zh) | Janus激酶抑制剂 | |
US8921368B2 (en) | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | |
TW201350476A (zh) | 用於調節表皮生長因子受體(egfr)活性之化合物及組合物 | |
JP7168149B2 (ja) | Fgfr阻害剤としてのピラジン-2(1h)-オン系化合物 | |
JP2008510006A (ja) | 化合物 | |
JP2020532545A (ja) | スピロ環化合物並びにその作製及び使用方法 | |
JP7237010B2 (ja) | Hdac6選択的阻害剤およびその製造方法と使用 | |
US10017507B2 (en) | Diaza-benzofluoranthrene compounds | |
JP2019522059A (ja) | S1p1アゴニスト及びその応用 | |
KR20170015339A (ko) | 혈액응고인자 Xa 억제제로서의 히드라진 화합물 | |
CN111479810B (zh) | Jak抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170915 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170915 |
|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170915 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180619 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180919 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20180919 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20180920 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190205 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190514 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190813 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20200114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200408 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20200526 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200721 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200728 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6742323 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |